INCIDENCE OF ENDOMETRIAL HYPERPLASIA IN 100 CASES PRESENTING WITH POLYMENORRHAGIA/MENORRHAGIA IN PERIMENUPAUSAL WOMEN
Abstract
Background: To study the Incidence of endometrial hyperplasia in perimenupausal women presentingwith polymenorrhagia/menorrhagia. This observational study was conducted at Gynae ‘B’ unit ofKhyber Teaching Hospital Peshawar from January 2000 to December 2001. Methods: One hundredconsecutive patients who presented at Gynaecology OPD with Polymenorrhagia/ Menorrhagia wereregistered and incidence of endometrial hyperplasia evaluated in them. All women were above 45 yearsof age. Post-menopausal bleeding cases were excluded from the study. Results: Out of 100 patients, 15patients were found to have endometrial hyperplasia, 10 patients (66.6%) simple cystic hyperplasia, 3patients (20.0%) had adenomotous hyperplasia, 2 patients (13.3%) had atypical hyperplasia, 8 patients(53.3%) with menorrhagia, 1 (6.6%) with polymenorrhagia, and 6 patients (40.0%) withpolymenorrhoea. Duration of symptoms was from 4 months to 1 year. Thirteen (86.6%) patients weretreated medically, 5 patients (33.33%) needed surgical treatment following medical treatment, 2patients (13.3%) underwent Total Abdominal Hysterectomy (TAH) and Bilateral Salpingooophorectomy (BSO) who were 51–53 years of age with atypical hyperplasia. Conclusion:endometrial hyperplasia is a pre-malignant condition; if treated in time, incidence can be reduced andearly treatment can increase life expectancy and quality in women over age of 45 years.Keyword: Menorrhagia, Polymenorrhagia, Endometrial hyperplasia, Transvaginal Ultrasound, TVSReferences
Kurman RJ, Kamiriski PF, Norris HJ. The behavior of
endometrial hyperplasia; A long term study of untreated
endometrial hyperplasia in 170 patients. Cancer
;56:403–12.
Wentz WB. Progestin therapy in endometrial hyperplasia.
Gynaecol Oncol 1974;2:362–7.
Mishal DR, Droegmuller-W, Merbot-AL. Abdominal uterine
bleeding. Corhensive Gynaecology. 953–64.
Niwa K, Morishita S, Hashimoto M, Itoh T, Fujimoto J, Mori
H, et al. Effects of tamoxifen on endometrial carcinogenesis
in mice. Jpn J Cancer Res 1998;89(5):502–9.
Fox H, Langley FA. eds. Tumours of ovary. London:
Heinemann Medical;1976. p.119–37.
Tavasolli F, Krawz FT. Endometrial lesions in uteri resected
for atypical endometrial hyperplasia. Am J Clin Pathol
;70:770–9.
Colgan TJ, Norris HJ, Foster W, Kurman RJ, Fox CH..
Predicting the outcome of endometrial hyperplasia by
quantitive analysis of nuclear features using a linear
discriminate function. Int J Gynaecol Pathol 1983;1(4):347–52.
Campbell PE, Barter RA. The significance of atypical
hyperplasia. J Obstet Gynaecol Br Commonw 1961;68:668–72.
Sommers SC. The clinical significance of endometrial
hyperplasia and its early diagnosis. In Barber HRK, Graber
EA (eds): Gynecologic Oncology. Baltimore: Williams &
Wilkins; 1970.
Horbelt DV, Roberts DK, Parmley TH, Walker NJ.
Ultrastructure of the microvasculature in human endometrial
hyperplasia. Am J Obstet Gynecol 1996;174(1 Pt-1):174–83.
Mughal N. Diagnostic Value of endometrial curettage, in
abnormal uterine bleeding. J Pak Med Assoc
;47(12):295–8.
Fayyaz S, Majeed SS. Audit of Gynaecological
hysterectomies. J Postgrad Med Inst 2001;15(2):208–12.
Riffat Jalil. A study to correlate the indication of abdominal
hysterectomy with histopathological findings. 1998. (FCPS
Dissertation).
Adil F. D&C in excessive and abnormal uterine bleeding (2
year study) Obst Gynae B Unit Dow Medical College
Karachi. 1997 (FCPS Dissertation)
Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima
A, Noda K, et al. The behavior of endometrial hyperplasia: a
prospective study. Endometrial Hyperplasia Study Group. J
Obstet Gynaecol Res 1997;23(3):223–30.
Menwissen JH et al 1996, Endometrial Biopsy the female
patient 1993,4:19–23.
Bakos O, Heimer G. Transvaginal Ultrasonography
evaluation of the endometirum related to the histological
findings in pre-and permenopausal women. Gynaecol Obstet
Invest 1998;45(3):199–204.
el-Ahmady O, Gad M, el-Sheimy R, Halim AB, Eissa
S, Hassan F, et al. Comparitive study between sonography
pathology and UGP in women with periomenopausal
bleeding. Anticancer Res 1996;16(4B):2309–13.
Ben Yehuda OM, Kim YB, Leuchter RS. Does Hysteroscopy
improve upon the sensitivity of dilatation and curettage in the
diagnosis of endometrial hyperplasia or carcinoma?
Gynaecol Oncol1998;68(1):4–7.
Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia
and the risk of endometrial carcinoma. Singapore Med J
;38(1):11–5.
Gücer F, Reich O, Tamussino K, Bader AA, Pieber D, Schöll
W, et al. Concomitant endometrial Hyperplasia in patients with
endometrial carcinoma. Gynaecol Oncol 1998;69(1)64–8.
Colacurci N, De Placido G, Mollo A, Perino A, Cittadini E.
Short term use of Goserlin Depot in the treatment of
dysfunctional uterine bleeding. Clin Exp Obstet
Gynecol 1995;22:212–9.
Gimpalson RJ. Not so benign endometrial hyperplasia:
endometrial cancer after endometrial ablation. J Am Assoc
Gynaecol Laprarosc 1997;4(4):507–11.
